ONAPGO (apomorphine HCL) injection, for sc infusion is a continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease patients.

6 days ago · Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch.

Feb 4, 2025 · According to Supernus, Onapgo will be available in the second quarter of 2025, and the company will provide a support system at launch, including a robust nurse education …

6 days ago · Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch.

6 days ago · Supernus Pharmaceuticals, Inc. ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced …

Feb 4, 2025 · 1 ONAPGO. Package insert. Supernus Pharmaceuticals, Inc. *Efficacy results from the analysis of data from the TOLEDO study using the FDA’s preferred methodology, mixed …

Feb 4, 2025 · Nearly 4 and a half years since its original submission, the FDA has approved Supernus Pharmaceuticals’ investigational agent SPN-830 (Onapgo) as the first and only …

Feb 4, 2025 · Onapgo is a wearable pump designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). ... Supernus’ Apokyn contributed $19.9 million to …

5 days ago · The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection to treat motor fluctuations in …

6 days ago · ONAPGO TM was brought to market by the pharmaceutical company Supernus, which reports that the therapy will be available for use in the U.S. within the next few months. …